JP2008528612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528612A5 JP2008528612A5 JP2007553242A JP2007553242A JP2008528612A5 JP 2008528612 A5 JP2008528612 A5 JP 2008528612A5 JP 2007553242 A JP2007553242 A JP 2007553242A JP 2007553242 A JP2007553242 A JP 2007553242A JP 2008528612 A5 JP2008528612 A5 JP 2008528612A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- pta
- formulation
- antibody
- atcc deposit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 25
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 22
- 238000009472 formulation Methods 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 229960002885 histidine Drugs 0.000 claims 12
- 235000010355 mannitol Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 6
- 229920000053 polysorbate 80 Polymers 0.000 claims 6
- 229940068968 polysorbate 80 Drugs 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- 239000011521 glass Substances 0.000 claims 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 230000003942 amyloidogenic effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64863105P | 2005-01-28 | 2005-01-28 | |
| US60/648,631 | 2005-01-28 | ||
| PCT/US2006/002837 WO2006083689A2 (en) | 2005-01-28 | 2006-01-27 | Anti a beta antibody formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008528612A JP2008528612A (ja) | 2008-07-31 |
| JP2008528612A5 true JP2008528612A5 (cg-RX-API-DMAC7.html) | 2009-03-19 |
| JP4977625B2 JP4977625B2 (ja) | 2012-07-18 |
Family
ID=36686080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553242A Expired - Fee Related JP4977625B2 (ja) | 2005-01-28 | 2006-01-27 | 抗ａベータ抗体製剤 |
Country Status (29)
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| JP5362164B2 (ja) * | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| MXPA05008156A (es) * | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| TWI374893B (en) * | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CN101287471B (zh) * | 2004-10-05 | 2012-10-03 | 杨森阿尔茨海默氏症免疫治疗公司 | 改善重组蛋白制备的方法和组合物 |
| CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| TW200636066A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| JP5270337B2 (ja) * | 2005-06-17 | 2013-08-21 | ヤンセン アルツハイマー イミュノセラピー | 抗Ａβ抗体を精製する方法 |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| MX358175B (es) | 2005-12-12 | 2018-08-08 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| DK3219328T3 (da) * | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| US8025878B2 (en) * | 2006-03-23 | 2011-09-27 | Bioarctic Neuroscience Ab | Protofibril selective antibodies and the use thereof |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| WO2010044803A1 (en) * | 2008-10-17 | 2010-04-22 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US7892544B2 (en) | 2006-07-14 | 2011-02-22 | Ac Immune Sa | Humanized anti-beta-amyloid antibody |
| US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| MX2009006199A (es) * | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Formulacion parenteral de anticuerpos abeta. |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| KR20100016661A (ko) * | 2007-04-18 | 2010-02-12 | 얀센 알츠하이머 이뮤노테라피 | 대뇌 아밀로이드 혈관병증의 예방 및 치료 |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
| PT2238166E (pt) | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
| RU2542967C2 (ru) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
| NZ601858A (en) * | 2007-10-05 | 2014-03-28 | Genentech Inc | Methods and compositions for diagnosis and treatment of amyloidosis |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
| RU2011100127A (ru) * | 2008-06-12 | 2012-07-20 | Аффирис Аг (At) | Соединение, содержащее пептид, для лечения симптомов болезни паркинсона |
| JP5705115B2 (ja) * | 2008-09-10 | 2015-04-22 | ジェネンテック， インコーポレイテッド | 蛋白質の酸化的分解の予防のための組成物および方法 |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| PH12012501742A1 (en) | 2010-03-01 | 2022-03-21 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| BR112012022102A2 (pt) | 2010-03-03 | 2017-01-10 | Boehringer Ingelheim Int | polipeptídeos de ligação a a-beta. |
| CN102933601B (zh) | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| JP2013544762A (ja) | 2010-09-17 | 2013-12-19 | バクスター、インターナショナル、インコーポレイテッド | 弱酸性〜中性のｐＨにおける、塩化ナトリウムを有する水性製剤を介した免疫グロブリンおよび他のタンパク質の安定化 |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| PL2697369T3 (pl) | 2011-03-25 | 2018-12-31 | F.Hoffmann-La Roche Ag | Nowe sposoby oczyszczania białek |
| EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| ES2646717T3 (es) * | 2011-05-02 | 2017-12-15 | Millennium Pharmaceuticals, Inc. | Formulación para anticuerpo anti- 4 7 |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| JP6431372B2 (ja) | 2011-10-25 | 2018-11-28 | プロシーナ バイオサイエンシーズ リミテッド | 抗体製剤および方法 |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| US20140314741A1 (en) * | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
| KR20240090993A (ko) | 2013-08-30 | 2024-06-21 | 다케다 야쿠힌 고교 가부시키가이샤 | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 |
| TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| CN112390881B (zh) | 2014-07-10 | 2025-02-21 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
| EP3194439B1 (en) | 2014-09-19 | 2022-01-19 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| EP3825324A1 (en) | 2014-10-24 | 2021-05-26 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| EP3292147A1 (en) * | 2015-05-07 | 2018-03-14 | NovImmune SA | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| WO2016207240A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CN114057884A (zh) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| JP6722293B2 (ja) | 2016-02-19 | 2020-07-15 | シワ コーポレーション | 終末糖化産物（ａｇｅ）に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
| GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CA3057829A1 (en) * | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| KR20240122572A (ko) * | 2017-08-08 | 2024-08-12 | 체에스엘 베링 아게 | 헤모펙신 제형 |
| AU2018321335B2 (en) * | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| WO2019040608A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | PHARMACEUTICAL COMPOSITIONS AND DOSAGE SCHEMES CONTAINING ANTI-ALPHA (V) BETA ANTIBODIES (6) |
| CN111201042B (zh) * | 2017-09-19 | 2024-05-10 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| KR20220011697A (ko) | 2019-05-22 | 2022-01-28 | 바이오비에 아이앤씨. | 테를리프레신 제형 |
| IL291929A (en) * | 2019-10-06 | 2022-06-01 | Brim Biotechnology Inc | Compositions comprising pedf-derived short peptides (pdsp) and uses thereof |
| IL300059A (en) | 2020-07-23 | 2023-03-01 | Othair Prothena Ltd | Anti-Abata antibodies |
| WO2024246085A1 (en) | 2023-05-31 | 2024-12-05 | F. Hoffmann-La Roche Ag | Therapeutic use of bispecific anti-abeta/tfr antibodies |
| WO2025147562A1 (en) * | 2024-01-05 | 2025-07-10 | Othair Prothena Limited | Methods of treating neurological disorders with anti-abeta antibodies |
| WO2025240435A1 (en) * | 2024-05-14 | 2025-11-20 | Othair Prothena Limited | Methods of treating neurological disorders with anti-abeta antibodies |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP2727112B2 (ja) * | 1988-04-26 | 1998-03-11 | コニカ株式会社 | 安定なペルオキシダーゼ組成物及び安定な抗体組成物 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| US5658727A (en) | 1991-04-10 | 1997-08-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP2966592B2 (ja) * | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US6270757B1 (en) | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| EP0985033A4 (en) | 1997-04-04 | 2005-07-13 | Biosite Inc | POLYVALENT AND POLYCLONAL LIBRARIES |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| CA2312475C (en) | 1997-12-03 | 2010-08-03 | Brigham And Women's Hospital | Method of suppressing .beta.-amyloid-related changes in alzheimer's disease |
| US20050059591A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US20050059802A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
| US7282570B2 (en) * | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| ES2312348T3 (es) | 1999-06-16 | 2009-03-01 | Boston Biomedical Research Institute | Control inmunologico de niveles de beta-amiloide in vivo. |
| PL360914A1 (en) | 1999-07-15 | 2004-09-20 | Genetics Institute Inc. | Formulations for il-11 |
| MXPA02008145A (es) | 2000-02-24 | 2004-04-05 | Univ Washington | Anticuerpos humanizados que secuestran al peptido beta amiloide. |
| JP2003516929A (ja) * | 2000-06-01 | 2003-05-20 | ニユーララブ・リミテツド | アミロイド形成性疾患の予防および治療 |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US6916745B2 (en) * | 2003-05-20 | 2005-07-12 | Fairchild Semiconductor Corporation | Structure and method for forming a trench MOSFET having self-aligned features |
| ES2437875T3 (es) | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
| ATE409047T1 (de) | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| ES2338218T3 (es) * | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
| AU2002324468A1 (en) | 2001-08-17 | 2003-03-03 | Eli Lilly And Company | Rapid improvement of cognition in conditions related to abeta |
| EP1432444A4 (en) * | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| US20030171556A1 (en) | 2001-12-13 | 2003-09-11 | Chi-Bom Chae | Beta-amyloid binding factors and inhibitors thereof |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| MXPA05008156A (es) | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| JP4869064B2 (ja) * | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| TWI379839B (en) | 2003-12-17 | 2012-12-21 | Wyeth Llc | Aβ immunogenic peptide carrier conjugates and methods of producing same |
| SI1701968T1 (sl) | 2003-12-17 | 2015-08-31 | Wyeth Llc | Imunogeni konjugati peptidnih nosilcev in postopek izdelave istih |
| EP1563794B1 (en) * | 2004-02-17 | 2007-04-25 | Tyco Healthcare Group Lp | Surgical stapling apparatus with locking mechanism |
| CN101287471B (zh) | 2004-10-05 | 2012-10-03 | 杨森阿尔茨海默氏症免疫治疗公司 | 改善重组蛋白制备的方法和组合物 |
| US20060160161A1 (en) | 2004-10-26 | 2006-07-20 | Elan Pharmaceuticals, Inc. | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
| US20060153772A1 (en) | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
| CA2589017A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid beta antibodies for use in improving cognition |
| CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| TW200636066A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
| KR20070107079A (ko) | 2005-01-28 | 2007-11-06 | 와이어쓰 | 안정화된 액체 폴리펩타이드 제형 |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| JP5270337B2 (ja) | 2005-06-17 | 2013-08-21 | ヤンセン アルツハイマー イミュノセラピー | 抗Ａβ抗体を精製する方法 |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| KR20100016661A (ko) * | 2007-04-18 | 2010-02-12 | 얀센 알츠하이머 이뮤노테라피 | 대뇌 아밀로이드 혈관병증의 예방 및 치료 |
| US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2006
- 2006-01-26 GT GT200600031A patent/GT200600031A/es unknown
- 2006-01-27 CN CN2006800035305A patent/CN101262884B/zh not_active Expired - Fee Related
- 2006-01-27 BR BRPI0607039-6A patent/BRPI0607039A2/pt not_active IP Right Cessation
- 2006-01-27 ZA ZA200705710A patent/ZA200705710B/xx unknown
- 2006-01-27 AU AU2006211184A patent/AU2006211184B8/en not_active Ceased
- 2006-01-27 MX MX2007009050A patent/MX2007009050A/es active IP Right Grant
- 2006-01-27 EA EA201100180A patent/EA021507B1/ru not_active IP Right Cessation
- 2006-01-27 NZ NZ556393A patent/NZ556393A/en not_active IP Right Cessation
- 2006-01-27 EP EP20110164194 patent/EP2392353A1/en not_active Withdrawn
- 2006-01-27 SI SI200631442T patent/SI1853310T1/sl unknown
- 2006-01-27 EP EP06719621A patent/EP1853310B1/en active Active
- 2006-01-27 CN CN201210172792.1A patent/CN103768009B/zh not_active Expired - Fee Related
- 2006-01-27 UA UAA200708609A patent/UA87549C2/ru unknown
- 2006-01-27 ES ES06719621T patent/ES2391407T3/es active Active
- 2006-01-27 PE PE2006000114A patent/PE20060879A1/es not_active Application Discontinuation
- 2006-01-27 MY MYPI20060416A patent/MY177052A/en unknown
- 2006-01-27 KR KR1020077019596A patent/KR101188060B1/ko not_active Expired - Fee Related
- 2006-01-27 PL PL06719621T patent/PL1853310T3/pl unknown
- 2006-01-27 US US11/342,353 patent/US7635473B2/en active Active
- 2006-01-27 DO DO2006000021A patent/DOP2006000021A/es unknown
- 2006-01-27 CA CA2593122A patent/CA2593122C/en not_active Expired - Fee Related
- 2006-01-27 EA EA200701596A patent/EA015147B1/ru not_active IP Right Cessation
- 2006-01-27 TW TW095103326A patent/TWI398263B/zh not_active IP Right Cessation
- 2006-01-27 WO PCT/US2006/002837 patent/WO2006083689A2/en not_active Ceased
- 2006-01-27 AR ARP060100315A patent/AR052198A1/es not_active Application Discontinuation
- 2006-01-27 UY UY29351A patent/UY29351A1/es not_active Application Discontinuation
- 2006-01-27 PT PT06719621T patent/PT1853310E/pt unknown
- 2006-01-27 DK DK06719621.2T patent/DK1853310T3/da active
- 2006-01-27 JP JP2007553242A patent/JP4977625B2/ja not_active Expired - Fee Related
- 2006-01-29 JO JO200629A patent/JO2740B1/en active
-
2007
- 2007-06-28 NO NO20073305A patent/NO20073305L/no not_active Application Discontinuation
- 2007-07-12 IL IL184599A patent/IL184599A/en not_active IP Right Cessation
-
2009
- 2009-12-14 US US12/637,508 patent/US8318164B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528612A5 (cg-RX-API-DMAC7.html) | ||
| US11498959B2 (en) | Anti-CGRP antibody formulation | |
| TWI738632B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| JP2020203889A (ja) | 抗体製剤 | |
| AU2020202577B2 (en) | Aripiprazole formulations having increased injection speeds | |
| JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| JP2020169200A (ja) | 結晶性抗体製剤 | |
| JP2020536926A (ja) | Ｌ−エピネフリンの安定化注射用医薬用組成物 | |
| JP2016074699A (ja) | プロセス | |
| AU2021269450B2 (en) | Parenteral Formulation comprising Siponimod | |
| JP6609637B2 (ja) | ＴＧＦ−β１遺伝子の発現を抑制する一本鎖核酸分子を安定に含有する組成物 | |
| JP6950966B2 (ja) | スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法 | |
| EP4420660A1 (en) | Use of edaravone in treatment of autism spectrum disorder | |
| CN114306225A (zh) | 稳定的艾博韦泰组合物 | |
| CN106535913A (zh) | 神经活性肽的稳定组合物 | |
| JP7703245B2 (ja) | ケトロラック液体組成物、その製造方法及び応用 | |
| JP2000219628A (ja) | アラトロフロキサシンの予め混合した注射用組成物 | |
| CN110237033A (zh) | 一种2,4二硝基苯酚注射液及其制备方法和用途 | |
| JP2012504589A (ja) | 炭疽菌ワクチン製剤とその用途 | |
| WO2025077751A1 (zh) | Glp-1肽组合物及其用途 | |
| US20250319066A1 (en) | Injectable dmt formulations | |
| CN108289840A (zh) | 用于静脉内注射Danirixin的制剂 | |
| CN118317787A (zh) | 包含Fab-PEG的制剂 | |
| JP2019510057A (ja) | 経口投与されるｇｈｂ又はその治療上許容可能な塩の一つの即時放出のための単位投薬量、および禁酒を維持するためのその使用 | |
| TW200404777A (en) | Treatment of nonallergic rhinitis by selective phosphodiesterase 4 inhibitors |